INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12…Original Article
FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis
